XWELL Inc (XWEL)
1.82
+0.03
(+1.68%)
USD |
NASDAQ |
May 06, 14:18
XWELL SG&A Expense (Quarterly): 6.392M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 6.392M |
September 30, 2023 | 3.906M |
June 30, 2023 | 5.099M |
March 31, 2023 | 6.091M |
December 31, 2022 | 9.223M |
September 30, 2022 | 5.706M |
June 30, 2022 | 6.719M |
March 31, 2022 | 10.19M |
December 31, 2021 | 9.849M |
September 30, 2021 | 5.196M |
June 30, 2021 | 4.646M |
March 31, 2021 | 4.508M |
December 31, 2020 | 4.968M |
September 30, 2020 | 4.368M |
June 30, 2020 | 3.371M |
March 31, 2020 | 3.233M |
December 31, 2019 | 5.115M |
September 30, 2019 | 3.108M |
June 30, 2019 | 2.496M |
March 31, 2019 | 3.60M |
December 31, 2018 | 3.797M |
September 30, 2018 | 3.943M |
June 30, 2018 | 3.904M |
March 31, 2018 | 4.596M |
December 31, 2017 | 3.54M |
Date | Value |
---|---|
September 30, 2017 | 4.18M |
June 30, 2017 | 3.864M |
March 31, 2017 | 4.993M |
December 31, 2016 | 1.643M |
September 30, 2016 | 3.564M |
June 30, 2016 | 2.316M |
March 31, 2016 | 2.952M |
December 31, 2015 | 2.679M |
September 30, 2015 | 2.095M |
June 30, 2015 | 2.298M |
March 31, 2015 | 2.998M |
December 31, 2014 | 3.779M |
September 30, 2014 | 4.148M |
June 30, 2014 | 4.203M |
March 31, 2014 | 4.243M |
December 31, 2013 | 3.877M |
September 30, 2013 | 3.703M |
June 30, 2013 | 3.759M |
March 31, 2013 | 9.39M |
December 31, 2012 | 2.718M |
September 30, 2012 | 6.364M |
June 30, 2012 | 0.529M |
March 31, 2012 | 0.616M |
December 31, 2011 | 1.125M |
September 30, 2011 | 0.323M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.496M
Minimum
Jun 2019
10.19M
Maximum
Mar 2022
5.483M
Average
5.099M
Median
Jun 2023
SG&A Expense (Quarterly) Benchmarks
Fonar Corp | 5.587M |
ProPhase Labs Inc | 8.022M |
Applied DNA Sciences Inc | 3.084M |
Veracyte Inc | 48.21M |
OncoCyte Corp | 2.391M |